{"id":"W1988367968","doi":"10.1182/blood-2012-02-408773","title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network; University of British Columbia; London Health Sciences Centre; Jewish General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Obinutuzumab; Medicine; Neutropenia; Internal medicine; Maintenance therapy; Tolerability; Regimen; Rituximab; Phases of clinical research; Population; CD20; Gastroenterology; Surgery; Lymphoma; Oncology; Clinical trial; Chemotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001438551,0.001519594,0.002392263,0.0004558737,0.0005707807,0.0007499512,0.0009200115,0.001126228,0.001723926],"category_scores_gemma":[0.001060837,0.0006754906,0.001079225,0.0003793516,0.0007707932,0.000819625,0.0003420612,0.002715471,0.0005153833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007552152,"about_ca_system_score_gemma":0.001411328,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000786128,"about_ca_topic_score_gemma":0.001622575,"domain_scores_codex":[0.9995247,0.0002088758,0.00001966961,0.00008568045,0.00003861758,0.0001225222],"domain_scores_gemma":[0.9992068,0.0001311485,0.0001633636,0.00006252243,0.00003929857,0.0003968992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.628311,0.1759596,0.01205221,0.0007665263,0.0009678921,0.0006061062,0.0005787854,0.003057937,0.04352934,0.0002624659,0.001924909,0.1319833],"study_design_scores_gemma":[0.1916632,0.7965205,0.007761988,0.00002210683,0.000179556,0.0001978145,0.00003364754,0.0006220294,0.001921853,0.00008616941,0.0009708927,0.00002021763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996407,0.001327339,0.0002862426,0.0001436162,0.00007275277,0.001044207,0.0001901383,0.00003004826,0.0004986704],"genre_scores_gemma":[0.9931093,0.001311544,0.001028509,0.0004737149,0.000201544,0.001717017,0.0008413543,0.00001696273,0.001300079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002392263,"threshold_uncertainty_score":0.007607937,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009608775374167903,"score_gpt":0.2575599199963363,"score_spread":0.2479511446221684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}